Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025. Second discovery partnership in obesity initiated.
Organizations Involved
Eli Lilly & Company, Pfizer
Founders
Flagship Pioneering
Company Description
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.